Paige E. Selvy

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.

Sarah A. Scott, C. Lindsley, M. Armstrong, 2009, Bioorganic & medicinal chemistry letters.

Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Sarah A. Scott, C. Lindsley, H. Brown, 2009, Nature chemical biology.

Design, Synthesis and Biological Evaluation of Halogenated N- (2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8- yl)ethylbenzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 (PLD2) Inhibitor

Sarah A. Scott, S. Jadhav, C. Lindsley, 2011 .

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.

Sarah A. Scott, Sydney L. Stoops, C. Lindsley, 2009, Bioorganic & medicinal chemistry letters.

Phospholipase D: enzymology, functionality, and chemical modulation.

C. Lindsley, H. Brown, R. Lavieri, 2011, Chemical reviews.

Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Sarah A. Scott, S. Jadhav, C. Lindsley, 2010, Journal of medicinal chemistry.

Evidence that alpha-synuclein does not inhibit phospholipase D.

D. Selkoe, S. Lindquist, A. Gitler, 2009, Biochemistry.

Evidence that α -Synuclein Does Not Inhibit Phospholipase D †

D. Selkoe, S. Lindquist, A. Gitler, 2009 .